Description
Vesugen (Lys-Glu-Asp) is a synthetic tripeptide of the Khavinson bioregulator class with tissue-specific action on the endothelium of blood vessels. The substance was developed at the St. Petersburg Institute for investigating age-related vascular dysfunction.
Per study reports Vesugen modulates gene expression in endothelial cells via the Khavinson epigenetic mechanism. Preclinical studies describe effects on NO synthase expression, adhesion molecule profile and endothelial repair cascades in aging models.
In Russian research literature Vesugen is described as cardiovascular aging bioregulator, often combined with Cardiogen (heart muscle) for system-wide vascular research setups.
Typical application is subcutaneous in 10-20 day courses two to three times per year.
You can order Vesugen as lyophilized peptide in 10-pack at 20mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Vesugen is classified as very mild in the available literature and is among the most well tolerated compounds of the Khavinson bioregulator class. In the available preclinical and limited human studies, no relevant toxic effects have been documented.
Observed in research and reports:
- Injection site: mild redness or transient irritation with subcutaneous use is the most common observation. The tripeptide itself is considered low-reactivity.
- Very thin human data: the data base consists almost entirely of small, Russian-language studies from the Khavinson environment. Independent peer-reviewed replication and robust long-term data on vascular use are absent.
- Course-based pattern: the use described occurs in short 10-20 day courses. No data exist on the safety profile of continuous administration.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging - Advances in Gerontology 2015, Khavinson et al: epigenetic regulation of endothelial cell proliferation by short peptides.
- Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease - Bulletin of Experimental Biology and Medicine 2021, Khavinson, Lin’kova and Umnov: KED tripeptide in molecular-genetic regulation, relevant to the vascular-neuronal interface.
- Peptidergic Regulation of Expression of Genes Encoding Antioxidant and Anti-Inflammatory Proteins - Bulletin of Experimental Biology and Medicine 2012, Khavinson et al: Khavinson peptides modulate antioxidant and anti-inflammatory gene expression - relevant to endothelial aging research.
- Peptide bioregulation of aging: results and prospects - Biogerontology 2009, Anisimov and Khavinson: overview of the Khavinson class with cardiovascular-relevant findings.
